EX 1000

Drug Profile

EX 1000

Alternative Names: EX1000

Latest Information Update: 24 Aug 2015

Price : $50

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics; Insulins
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 24 Jun 2008 Phase-II clinical trials in Type-2 diabetes mellitus in India (SC)
  • 24 Jun 2008 Phase-II clinical trials in Type-2 diabetes mellitus in South Africa (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top